Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  15: May | Apr | Mar | Feb | Jan | 14: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
06/11/2015 > patent applications in patent subcategories.
  
06/04/2015 > patent applications in patent subcategories.
  
05/28/2015 > 150 patent applications in 123 patent subcategories.

20150148283 - Novel casein protein product: The present invention relates to a process for producing a casein protein product comprising the steps of:—providing a casein concentrate starting material,—heat-treating the material,—cooling the heat-treated material,—subjecting the cooled material to a treatment with a crosslinking enzyme,—optionally subjecting the cooled material to a treatment with a coagulant and—processing the material... Agent:

20150148284 - Controlled release of phenolic opioids: A method of providing a patient with controlled release of a phenolic opioid using a prodrug capable, upon enzymatic activation, of releasing the phenolic opioid through intra-molecular cyclization leading to formation of a cyclic urea, carbamate or thiocarbamate.... Agent:

20150148285 - Salt and protease-resistance of antimicrobial peptide and the manufacture thereof: The present invention provides an antimicrobial peptide, wherein the amino terminal and/or carboxyl terminal of the peptide is linked with at least one artificial bulkyl amino acid to increase the salt resistance and protease resistance of the antimicrobial peptide. The antimicrobial peptide of the invention has a high salt resistance,... Agent: National Tsing Hua University

20150148286 - Potentiation of antibiotic treatment with a protein-lipid complex: Provided are compositions and methods for potentiating the effect of antibiotics. The compositions comprise a non-covalent complex of alpha-lactalbumin and fatty acid. The fatty acids are cis, unsaturated, C14 to C20 fatty acids. The complex and antibiotic can be administered to an individual together or separately. The antibiotic may be... Agent:

20150148287 - Catheter lock solution formulations: A liquid excipient is added to a lock solution formulation containing a lower alcohol and an anti-coagulant, antibiotic, and/or anti-microbial, such as the ethanol and tri-sodium citrate lock solution formulation, to prevent citrate from crystallizing in catheters made from silicone. The locking solution could include a liquid excipient, such as... Agent: Excelsior Medical Corporation

20150148288 - Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides: New insecticidal proteins, nucleotides, peptides, their expression in plants, methods of producing the peptides, new processes, production techniques, new peptides, new formulations, and new organisms, a process which increases the insecticidal peptide production yield from yeast expression systems. The present invention is also related and discloses selected endotoxins we call... Agent:

20150148289 - Pegylated oxm variants: A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.... Agent:

20150148290 - Macrocyclic modulators of the ghrelin receptor: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin... Agent:

20150148291 - Long-acting polypeptides and methods of producing and administering same: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.... Agent:

20150148292 - Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as 2-(2-Methoxybenzylidene)-1-indan-one; N-(4-arsonophenyl)glycine; 1,2-Benzenedicarboxylic acid, 1-(1-methylheptyl)ester; (4′-hydroxybiphenyl-4-yl) (phenyl)methanone; 2,2-dimethylchroman-6-carboxylic acid,... Agent:

20150148293 - Fibroblast growth factor mutants having improved functional half-life and methods of their use: Mutant fibroblast growth factor (FGF) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the Fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid... Agent:

20150148294 - Neuroendocrine tumor treatment: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.... Agent: Novartis Ag

20150148295 - Controlled-released peptide formulations: Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.... Agent:

20150148296 - Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent: A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.... Agent: Kinki University

20150148297 - Oleanoyl peptide composition and collagen enhancement: Disclosed is the a method of skin repair and firming, said method comprising the step of bringing into contact a pentapeptide conjugate of oleanolic acid with skin cells so that the effect of increased cellular communication at the molecular level to bring about gene and protein expression in the cells... Agent:

20150148298 - N-carboxyalkyl-auristatin and use thereof: The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such... Agent: Seattle Genetics, Inc.

20150148299 - Topical formulations and uses thereof: Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or... Agent:

20150148300 - Method and pharmaceutical composition for hair growth: The present disclosure relates to a method and a pharmaceutical composition for hair growth. The pharmaceutical composition includes a hair growth peptide (HGP) which includes all or part of the amino acid sequence SEQ ID No: 1. The method includes administering a hair growth peptide (HGP) which includes all or... Agent:

20150148301 - Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof: The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumour-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents,... Agent: Stemergie Biotechnology Sa A Corporation

20150148302 - Peptide inhibitors of caspase 2 activation: The present invention relates to compositions, including membrane permeable complexes, comprising a Caspase 2 activation inhibitory peptide having the amino acid sequence AFDAFC as well as methods of using the same for the treatment of neurodegenerative conditions associated with apoptosis in the central nervous system, such as Alzheimer's Disease, Mild... Agent: The Trustees Of Columbia University In The City Of New York

20150148303 - Peptides effectife in the treatment of conditions requiring the removal or destruction of cells: The embodiments are directed to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides.... Agent: Nymox Corporation

20150148304 - Novel peptides and analogs for use in the treatment of macrophage activation syndrome: Innate Defense Regulators (IDRs) interact with intracellular signaling events and modulate the innate defense response. Whereas much of the initial work with the IDRs focused on their role in fighting infection, recent results in animal models of chemotherapy- or radiation-induced mucositis and wound healing suggest that IDRs can be beneficial... Agent:

20150148305 - Composition and method for compounded therapy: The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. The transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine... Agent:

20150148306 - Compositions and methods for the treatment of inflammation: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of inflammation may be formulated for oral, buccal, rectal,... Agent:

20150148307 - Methods and compositions for the prognosis and treatment of relapsed leukemia: The present invention is directed to methods of prognosing relapsed leukemia in a subject. These methods are based on the detection of one or more relapse-specific gene mutations in a patient sample. The present invention further relates to methods of preventing and treating relapse leukemia in a subject based on... Agent: New York University

20150148308 - Pest control composition for harmful arthropods, and pest control method for harmful arthropods: e

20150148401 - Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells: The invention generally relates to methods for identifying and using anticancer therapeutic agents and, more particularly, to methods for identifying and using inhibitors of genes for inhibiting the growth and/or proliferation of MYC-driven tumor cells relative to normal cells.... Agent: Fred Huchinson Cancer Research Center

20150148402 - Modified small interfering rna molecules and methods of use: The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a... Agent: Novartis Ag

20150148404 - Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders: The current invention provides an improved oligonucleotide and its use for treating, ameliorating, preventing, delaying and/or treating a human cis-element repeat instability associated genetic neuromuscular or neurodegenerative disorder.... Agent:

20150148403 - Usp37 inactivation as a treatment for plzf/rara-associated acute promyelocytic leukemia: Method of regulating the stability and/or the level of the fusion protein PLZF/RARA are disclosed. Also disclosed are methods for identifying an agent as a regulator of the stability and/or the level of the fusion protein PLZF/RARA. Methods for identifying a therapeutic agent for treating PLZF/RARA-associated acute promyelocytic leukemia (APL)... Agent: Academia Sinica

20150148405 - Expression construct for a lin28-resistant let-7 precursor microrna: Precursor microRNA molecules that have been modified to prevent a protein involved in regulating developmental timing, oncogenesis, and/or neuronal growth from blocking processing of the precursor microRNA sequence to the mature microRNA are provided. Methods and kits for using the precursor microRNA molecules also are provided.... Agent: The Johns Hopkins University

20150148407 - Optogenetic inhibition of overactive neuronal activity: This disclosure relates to recombinant proteins, vectors, and methods of treating neurological conditions by exposing neurons to an opsin and luciferase in the presence of a luciferin. In certain embodiments, the disclosure relates to treating or preventing epilepsy or seizures comprising administering an effective amount of a vector that encodes... Agent:

20150148406 - Ttc8 as prognostic gene for progressive retinal atrophy in dogs: The invention relates to the use of the TTC8 gene as a biomarker for the prognosis of a canine mammal developing progressive retinal atrophy. The invention also relates to in vitro methods of prognosing progressive retinal atrophy in a canine mammal by detecting a genetic variation within the TTC8 gene... Agent: Animal Health Trust

20150148310 - Deuterium-enriched hyaluronan: The present invention generally relates to deuterium-enriched hyaluronan, d-HA, compositions containing the same, methods of using the same, and methods for making the same.... Agent:

20150148309 - Saccharide fraction from wheat, isolation process and field of use of the invention: Fractions extracted from wheat seeds germinated and macerated in water having a molecular weight comprised between 3 and 30 K Daltons are described.... Agent:

20150148311 - Non-systemic tgr5 agonists: or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, R3, R4, R8, R9, R10, R11, R12, A1, A2, X, Y and Z are as defined herein. Uses of such compounds as TGR5 antagonists and for treatment of various indications, including Type II diabetes meletus are also... Agent:

20150148312 - Osteoclast inhibitors for knee conditions: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.... Agent:

20150148313 - Macrocyclic factor viia inhibitors: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.... Agent:

20150148314 - Seriniquinones, melanoma-specific anticancer agents: There are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer.... Agent:

20150148315 - Method for improving drug treatments in mammals: An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration... Agent:

20150148316 - Lipid mixture for infant nutrition: The subject invention includes a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said phospholipid and uses thereof.... Agent:

20150148317 - Spinal cord injury, inflammation, and immune-disease: local controlled release of therapeutic agents: A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve... Agent: Massachusetts Institute Of Technology

20150148318 - Method for inhibiting growth of cancer cells: A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically... Agent:

20150148319 - Pharmaceutical formulation containing gelling agent: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Agent: The P.f. Laboratories, Inc.

20150148320 - Cosmetic use of salicylic acid derivatives: Cosmetic compositions comprising salicylic acid derivatives and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The salicylic acid derivatives are believed to have modulatory activity against one or more biochemical pathways implicated in the appearance of human skin.... Agent: Avon Products, Inc.

20150148321 - Substituted androst-4-ene diones: The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated... Agent:

20150148322 - Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma: e

20150148323 - Progesterone formulations: Various pharmaceutical formulations are disclosed herein. For example, a pharmaceutical formulation is disclosed comprising ultra-micronized progesterone.... Agent:

20150148324 - Formulations for the preparation of immediate release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process: Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, the tablets thus obtained and their preparation process, are described.... Agent: Valpharma International S.p.a.

20150148325 - Depot formulations of a hydrophobic active ingredient and methods for preparation thereof: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a hydrophobic active pharmaceutical ingredient (API) of low water solubility but readily dissolved in alcohols and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.... Agent:

20150148326 - Monobactams: The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.... Agent:

20150148330 - Carbamate compounds and of making and using same: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof,... Agent:

20150148328 - Novel 2,3-dihydro-1h-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof: The invention relates to the novel products of formula (I) with p, q=0, 1 or 2; R1=phenyl, pyridyl; —(CH2)m—Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; —SO2 —Rb; —CO—Re; m=1 or 2; Ra=aryl, heteroaryl, —CO-cycloalkyl, —CO-heterocycloalkyl, —CO—Rb, —C(Rb)═N—ORc, —CO 2 Rd, —CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl;... Agent:

20150148329 - Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis: Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs of riluzole have enhanced stability to... Agent:

20150148327 - Substituted pyridine spleen tyrosine kinase (syk) inhibitors: The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by... Agent: Merck Canada Inc.

20150148331 - Melt-extruded solid dispersions containing an apoptosis-inducing agent: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises... Agent:

20150148332 - Triazolo compounds as pde10 inhibitors: p

20150148333 - Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.... Agent:

20150148334 - Heteroaryls and uses thereof: e

20150148335 - Liquid formulation: The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.... Agent:

20150148336 - Methods for selecting medications: The invention provides methods for selecting and administering antidepressant medications to a patient based upon the patient's combination genotype and phenotype for a panel of genes.... Agent:

20150148337 - Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.... Agent: Constellation Pharmaceuticals, Inc.

20150148338 - Compositions comprising short-acting benzodiazepines: A composition is provided with a benzodiazepine and at least one hygroscopic excipient, in particular lactose and/or dextran.... Agent: Paion Uk Limited

20150148339 - Gastrin antagonists for treatment and prevention of osteoporosis: The provided embodiments are based in some aspects on the demonstration herein of a role for gastrin in regulating the aging gut-ovary axis and effects of targeting gastrin activity in reversing gastrin-mediated bone loss. Provided are methods, compositions and agents, including gastrin antagonists, for treatment, amelioration, and prevention of bone... Agent:

20150148342 - Bicyclic heterocycles as bet protein inhibitors: The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.... Agent: Incyte Corporation

20150148340 - Bicyclically substituted uracils and the use thereof: The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.... Agent: Bayer Pharma Aktiengesellschaft

20150148341 - Octahydro fused azadecalin glucocorticoid receptor modulators: The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.... Agent:

20150148343 - Chromenone analogs as sirtuin modulators: The present invention relates to novel sirtuin-modulating compounds, corresponding pharmaceutical compositions comprising a sirtuin-modulating compound, alone and/or in combination with another therapeutic agent, and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide... Agent: Glaxosmithkline, LLC

20150148344 - Quinoline derivatives as bromodomain inhibitors: e

20150148345 - Therapies for treating myeloproliferative disorders: Provided herein are methods, compositions, and kits for treating myeloproliferative disorders or neoplasms, including polycythemia vera, primary myelofibrosis, thrombocythemia, and essential thrombocythemia.... Agent:

20150148346 - Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.... Agent: Ptc Therapeutics Inc.

20150148347 - Indanyloxyphenylcyclopropanecarboxylic acids: wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such... Agent:

20150148348 - Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide,... Agent:

20150148349 - Complement pathway modulators and uses thereof: The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.... Agent: Novartis Ag

20150148350 - Drug for preventing/treating ocular disease: The present invention relates to a medicament for preventing or treating an ocular disease comprising cyclo-trans-4-L-hydroxyprolyl-L-serine as an active ingredient, a medicament for preventing or treating dry eye comprising the compound as an active ingredient, and, in particular, a medicament for preventing or treating dry eye having an action of... Agent:

20150148351 - Novel polymorphic forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or... Agent: Merck Patent Gmbh

20150148352 - Compositions and methods for the treatment angina and cardiovascular conditions: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of angina and cardiovascular conditions may be formulated for... Agent:

20150148353 - Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:... Agent: Lixte Biotechnology, Inc.

20150148354 - Crystalline forms of a purine derivative: The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process... Agent:

20150148355 - Transdermal silicone gel (silogel) compositions and methods of preparation: A silicone gel (“silogel”) composition used to deliver pharmaceutical products transdermally as well as a method for producing the silogel composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include silogel compositions which provide high viscosity/no separation due to API. They are not temperature-sensitive,... Agent:

20150148356 - Compounds for dry skin and anti-ageing application: The present invention relates to the cosmetic use, as agent for preventing and/or treating an aesthetic defect in the skin and/or its appendages that is associated with an imbalance in the differentiation and/or proliferation of the cells of an epidermis, of an effective amount of at least one compound represented... Agent:

20150148357 - Pyrrolo[2,3-d]pyrimidine compounds: Described herein is pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds.... Agent:

20150148358 - Novel dgat2 inhibitors: s

20150148359 - Selective inhibitors of undifferentiated cells: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1... Agent:

20150148360 - 3,5,n-trihydroxy-alkanamide and derivatives: method for making same and use thereof: The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating... Agent:

20150148361 - Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor: Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.... Agent:

20150148362 - Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease: The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and... Agent:

20150148363 - New azacyclic compounds: e

20150148364 - Artemisinin with berberine compositions and methods of making: An all-natural herbal composition and methods of preparing the same are provided. The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives and berberine, the two active substances mixed with various selected excipient compounds to form a single pill, tablet or capsule for treatment and prevention of malaria,... Agent:

20150148367 - Controlled release hydrocodone formulations: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.... Agent:

20150148368 - Crystalline, anhydrous forms of oxymorphone hydrochloride: Crystalline, anhydrous hydrochloride salts of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a method for the production of such salts, a pharmaceutical composition comprising an effective amount of such a salt and such a salt as a medicament and... Agent: Gr&#xdc Nenthal Gmbh

20150148366 - Particulates: A neutral poly(ethyl acrylate, methyl methacrylate) copolymer is employed as a carrier in the manufacture of pharmaceutical formulations containing an active ingredient. The formulations are preferably made by melt extrusion, and can have rubbery characteristics and can exhibit tamper resistance.... Agent:

20150148365 - Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds: The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of alpha, beta unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound.... Agent:

20150148369 - Chemical suppressors of neurotoxicity in synucleinopathic diseases: The current application relates to the use of a compound selected from the group consisting of camptothecin and its analog, 10-hydroxy camptothecin, topotecan, irinotecan, 18-beta-glycyrrhetinic acid and its analog, carbinoxolone, etoposide, topoisomerase inhibitors, and combinations thereof, for the treatment of a synucleinopathy disease or disorder such as Parkinson's disease.... Agent: Oxalys Pharmaceuticals

20150148370 - Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors: The invention described herein pertains to substituted indenoisoquinoline compounds as described herein, wherein RA, RD, W, X and Y are defined herein, pharmaceutical compositions and formulations comprising the indenoisoquinoline compounds, their synthesis, and methods for their use in the treatment and/or prevention of cancer.... Agent: Purdue Research Foundation

20150148371 - Novel neuromodulatory compounds: Provided herein are novel neuromodulatory compounds and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease, using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods... Agent:

20150148372 - Bicyclic heterocycles as bet protein inhibitors: The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.... Agent: Incyte Corporation

20150148375 - Bicyclic heterocycles as bet protein inhibitors: The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.... Agent: Incyte Corporation

20150148374 - Complement pathway modulators and uses thereof: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.... Agent: Novartis Ag

20150148373 - Heterocyclic guanidine f1f0-atpase inhibitors and therapeutic uses thereof: The invention provides heterocyclic guanidine compounds that inhibit F1F0-ATPase, and methods of using heterocyclic guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.... Agent:

20150148376 - Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use: The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.... Agent: Bayer Pharma Aktiengesellschaft

20150148377 - Quinoline derivatives: The invention relates to quinoline compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, W, U, Q, R1, R5 R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the... Agent: Novartis Ag

20150148378 - Anti-infective methods, compositions, and devices: The present invention provides methods for treating onychomycosis. In certain embodiments, the methods comprise comprising applying a pharmaceutically acceptable formulation containing 10% efinaconazole once a day for a treatment period of at least 36 weeks to the treatment area of an onychomycosis patient (a) without debriding the nail or nail-associated... Agent:

20150148379 - Injectable supersaturated acetaminophen solution for spinal administration: The present invention relates to an acetaminophen injectable aqueous solution for use in the treatment or in the prevention of pain by spinal administration, wherein said acetaminophen injectable solution is supersaturated. In certain embodiments, the acetaminophen injectable aqueous solution is administered simultaneously, separately or sequentially with a local anaesthetic by... Agent:

20150148380 - Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities: e

20150148381 - Substituted dihydropyrazolones for treating cardiovascular and hematological diseases: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.... Agent:

20150148382 - Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne: e

20150148383 - Methods for inhibiting or reversing epiretinal membrane formation: Described herein are treatment methods involving the administration of nicotinamide, which has been discovered to stabilize the normal phenotype of retinal pigment epithelial cells and to prevent retinal pigment epithelial cell proliferation. Diseases and disorders that can be treated according to the methods disclosed herein include, e.g., macular pucker, proliferative... Agent:

20150148384 - A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof: Disclosed herein are novel A-ring epoxidized triterpenoid compounds and derivatives thereof, including those of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds,... Agent: Reata Pharmaceuticals, Inc.

20150148385 - Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity: s

20150148386 - Oxazolidinone derivatives and composition for preventing or treating hepatitis c containing the same:

20150148387 - Methods of treatment, diagnosis and monitoring for methamphetamine toxicity which target ceramide metabolic pathways and cellular senescence: Methamphetamine is a highly addictive psychostimulant that causes profound damage to the brain and other body organs. Post mortem studies of human tissues have linked the use of this drug to diseases associated with aging, such as coronary atherosclerosis, but the molecular mechanism underlying these findings remains unknown. We report... Agent:

20150148388 - Chemical composition: The present invention is directed to stable chemical compositions and dosage forms that comprise nebivolol and valsartan and which achieve therapeutically effective plasma levels of both actives in hypertensive patients following administration, as well as to methods of lowering blood pressure and treating hypertension using such compositions and dosage forms.... Agent:

20150148389 - Methods for treating or preventing brain infections: The invention is directed to methods of treating organ specific infections in a host organism by administering compounds that target host receptors and/or host cellular signaling molecules to prevent a pathogen from infecting the organ. For example, the administration of a compound to prevent a pathogen from crossing the blood-brain... Agent:

20150148390 - Glioblastoma inhibiting compounds and their use: The present invention relates to glioblastoma inhibiting compounds, in particular gambogic acid amid and derivatives thereof for the treatment of glioblastoma. Moreover, methods for determining whether a treatment with the compounds of the invention is suitable for a patient are disclosed.... Agent: Life & Brain Gmbh

20150148391 - Stabilized pharmaceutical formulations comprising antineoplastic compounds: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.... Agent:

20150148392 - 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1: 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed.... Agent:

20150148393 - Cosmetic and/or pharmaceutical composition for the treatment of skin inflammation and related syndromes: The invention relates to a cosmetic and/or pharmaceutical composition in combination with suitable carriers for topical use, comprising a mixture consisting of methyl sulfonyl methane and at least one compound belonging to the class of 4-alkyl cyclohexanols, which is useful in the treatment of various inflammatory conditions such as rosacea.... Agent: General Topics S.r.l.

20150148395 - Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.... Agent: Allergan, Inc.

20150148394 - Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions: The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent:

20150148396 - Clonidine formulations in a biodegradable polymer carrier: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and... Agent:

20150148397 - Clonidine formulations in a biodegradable polymer carrier: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and... Agent:

20150148398 - Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic... Agent:

20150148399 - Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.... Agent:

20150148400 - O/w-emulsion-type topical pharmaceutical compositions containing a retinoid: O/W-emulsion-type topical pharmaceutical compositions including a retinoid are described. Also described, is a topical pharmaceutical composition including by way of an active pharmaceutical ingredient, a retinoid in a physiologically acceptable composition. Preparation methods and the use of the same in dermatology are also described.... Agent: Galderma Research & Development

20150148408 - Heterocyclic modulators of cannabinoid receptors: Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.... Agent:

20150148409 - Novel daidzein analogs as treatment for cancer: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.... Agent:

20150148411 - Compositions and methods for diagnosis and therapy of disorders related to alterations of myh9: Provided are compositions and methods related to mutations in the Myh9 gene for aiding in diagnosing a subject as having an aggressive form of a cancer, for identifying an individual as a candidate for treatment with a nuclear export inhibitor, for determining whether tumor cells have defective p53 nuclear transportation,... Agent:

20150148410 - Identification of specific apolipoprotein epitopes on circulating atherogenic low-density lipoprotein: An isolated peptidic fragment of apolipoprotein E comprises at least 3 contiguous amino acids, Including glycosylated threonine 194, threonine 289, serine 94, or serine 76 of SEQ ID NO.: 1, or any combination of those. An antibody capable of binding to the isolated peptidic fragment. A method of detecting a... Agent: Texas Heart Institute

20150148412 - Polymorphs of darunavir: The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection.... Agent: Mapi Pharma Limited

20150148413 - Desferrioxamine-metal complexes for the treatment of immune-related disorders: The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune... Agent:

20150148414 - Prostacyclin compounds, compositions and methods of use thereof: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in... Agent:

20150148415 - Derivatized dendrimer with low citotoxicity for in vivo, ex vivo, in vitro or in situ chelation of heavy metals or actinides: The present invention considers derivatized nanomolecules with proven effectiveness to bind to actinides, more specifically uranium, during in vivo, ex vivo, in vitro or in situ assays. When assayed in vivo, the invention showed a reduction in at least kidney damage due to exposition to uranium.... Agent:

20150148417 - Synthesis and biological studies of an isomeric mixture of (e/z) isoxylitones and its analogues: The invention relates to an anti-epileptic isoxylitone, 2,2′-(3,5,5-Trimethyl-2-cylohexen-1-ylidene)acetic acid.... Agent:

20150148416 - Use of saponified tall oil fatty acid: The present invention relates to use of a tall oil fatty acid which is modified by saponification in enhancing rumen fermentation and/or lowering rumen methane production.... Agent: Hankkija Oy

20150148419 - Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.... Agent:

20150148418 - Methods of treating hair related conditions: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.... Agent:

20150148420 - Methods for treating insomnia: Methods for treating insomnia are disclosed. The methods are directed to administering a pharmaceutically effective amount of baclofen to an individual suffering from insomnia. In addition, due to baclofen's positive effects on reducing nighttime reflux events, the present methods are directed to treating insomnia in patients that also suffer from... Agent:

20150148421 - Preservatives for cosmetic, toiletry and pharmaceutical compositions: A composition for and methods of preserving a topical cosmetic, toiletry or pharmaceutical formulation against microbiological contamination or growth are described in which the compositions used herein include at least one hydroxamic acid, salt or complex thereof, and the methods include addition of an effective amount of such compounds to... Agent: Inolex Investment Corporation

20150148422 - Method for preserving food and method for cleaning surfaces: A method for using urea sulfate as an anti-microbial agent, anti-mold agent, anti-fungal agent, and pH adjusting compound with the benefit of adding nitrogen and sulfur to the food supply. Urea sulfate provides a fundamental contribution to feed hygiene, as it suppresses the growth of mold and thus restricts the... Agent: Jsk Capital, LLC

20150148423 - Use of n-acetylcysteine amide in the treatment of disease and injury: This disclosure describes methods of use for N-acetylcysteine amide for the treatment of various disorders... Agent: Sentient Lifesciences, Inc.

20150148424 - Stable dosage forms of levomilnacipran: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.... Agent:

20150148425 - Antimicrobial composition exhibiting increased efficacy: Materials and apparatus are provided that exhibit increased efficacy. An antimicrobial composition includes a cationic active ingredient disposed within the antimicrobial composition. Further, the antimicrobial composition includes a lauramine oxide surfactant, the lauramine oxide surfactant comprising 0.9 to 1.9 weight percent of the antimicrobial composition. Further, the antimicrobial composition includes... Agent: The Dial Corporation

20150148426 - Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission: The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the... Agent: Integrative Research Laboratories Sweden Ab

20150148427 - Modified release formulations of memantine oral dosage forms: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active... Agent:

20150148428 - Micelle structure of nano preparation for diagnosis or treatment of cancer disease and preparation method thereof: Disclosed herein are a nanopreparation having a micelle structure for diagnosis or treatment of cancer diseases, and a method of preparing the same, and more particularly, a nanopreparation having a micelle structure available for diagonosis or treatment of cancer diseases and a method for preparing the same, wherein the nanopreparation... Agent:

20150148429 - Pain relieving system: An inventive composition including an amount of sugar or sugar alcohol, an amount of alkalizing agent, and an amount of vehicle; whereby the inventive composition is formulated for transdermal administration to alleviate one or more disorder symptoms, for example neurogenic pain, or to treat one or more disorders, for example... Agent: Nova Neura, LLC

20150148430 - 2,5-dialkyl-4-h/halo/ether-phenol compounds:

20150148431 - Transdermal delivery patch: A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.... Agent:

20150148432 - Assessing susceptibility to vascular disorders: The invention provides methods and reagents for determination of risk and treatment of a vascular disorder such as abdominal aortic aneurysm (AAA) by detecting presence of gene polymorphisms and/or genetic profiles associated with an elevated or a reduced risk of the disorder. In an embodiment, the present invention provides methods... Agent:

  
05/21/2015 > 211 patent applications in 164 patent subcategories.

20150141320 - Compositions and methods for modulating gene expression: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital

20150141321 - Compound and method for treating myotonic dystrophy: Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1.... Agent:

20150141322 - Therapeutic agent, treatment method and inspection method for diseases caused by activation or neutrophils: The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (HRG) as an active ingredient, and provides a therapeutic agent for diseases caused by... Agent: National University Corporation Okayama University

20150141323 - Peptide-oligourea chimeric compounds and methods of their use: The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts... Agent:

20150141324 - Stable peptide-based furin inhibitors: It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or... Agent: Socpra Sciences Sante Et Humaines S.e.c.

20150141325 - Identification of inhibitors of a bacterial stress response: A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription... Agent:

20150141326 - Antiviral compounds: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent:

20150141327 - Fibroblast growth factor 21 variants: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.... Agent:

20150141328 - Stimulation of human meibomian gland function: Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a PLD-inducing compound, such as the cationic amphiphilic drugs (e.g. azithromycin), androgen or an... Agent:

20150141329 - Neurturin molecules: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of... Agent:

20150141330 - Apolipoprotein a-i mimics: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.... Agent:

20150141331 - Long-acting polypeptides and methods of producing and administering same: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.... Agent: Opko Biologics Ltd.

20150141332 - Methods for diagnosing osteoarthritis: Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor AB (PDGF-AB), platelet-derived growth factor BB (PDGF-BB), and epidermal growth factor (EGF). Tissue samples may... Agent: Biomet Biologics, LLC

20150141333 - Keratin bioceramic compositions: A malleable bone graft composition is described. The composition comprises: (a) keratose; (b) particulate filler; (c) antibiotic; and (d) water. The invention may be provided in sterile form in an container, and optionally lyophilized. Methods of treating a fracture with such compositions are also described.... Agent:

20150141334 - Composition for increasing muscle mass and a process for producing the same: Embodiments of the present invention are related to a method for producing a composition containing biologically active follistatin.... Agent:

20150141335 - Therapeutic uses of fibroblast growth factor 21 proteins: The present invention relates to therapeutic uses of human fibroblast growth factor 21 (FGF21) proteins.... Agent: Eli Lilly And Company

20150141337 - Manufacture of degarelix: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an... Agent: Ferring B.v.

20150141336 - Pancreatic peptide compounds and use: The invention relates to novel use of Pancreatic Polypeptides as well as novel Pancreatic Polypeptides and compositions thereof. Such peptides can be used in treating or preventing conditions responsive to Y4 and/or Y5 receptor activation, such as cachexia.... Agent:

20150141338 - Drug for preventing and/or treating polycystic kidney disease: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative,... Agent: Otsuka Pharmaceutical Co., Ltd.

20150141339 - Treatment of osteoporosis: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia.... Agent:

20150141340 - Method of treating and preventing ocular angiogenesis: The present invention provides methods for inhibiting ocular angiogenesis, vascular leakage, and/or edema. The methods comprise administering to a subject an agent comprising a caveolin scaffolding domain. The present invention further encompasses methods of treating and/or preventing ophthalmic conditions that are associated with ocular angiogenesis, vascular leakage, or edema.... Agent:

20150141341 - Methods and compositions for the treatment of beta-thalassemia: Methods and compositions for the treatment of β-thalassemia are provided. Methods and compositions restore or increase erythrocyte maturation in individuals afflicted with β-TM by preventing proteolysis of GATA-1 protein. Screening methods for identifying agents which bind heat shock protein 70 (HSP-70) and inhibit HSP-70 α-globin binding, but which allow GATA-1... Agent:

20150141342 - Blood borne mirna signature for the accurate diagnosis of pancreatic ductal adenocarcinoma: The differential expression of select miRNA in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls were measured. Patients (n=215) with treatment-naïve PDAC (n=77), CP with bile or pancreatic duct pathology (n=67), and controls (n=71) that had been prospectively enrolled in a Pancreatobiliary Disease Biorepository at the... Agent:

20150141343 - Sparc and methods of use thereof: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of... Agent:

20150141344 - Composition for repairing cartilage tissue, method for producing same, and use thereof: The present invention relates to a composition for repairing cartilage tissue, to a method for producing same, and to the use thereof. The present invention provides a composition for repairing cartilage tissue, which is obtained by mixing collagen and hyaluronic acid using a two-way syringe or a mixer, wherein the... Agent: Sewon Cellontech Co., Ltd.

20150141345 - Novel compounds and methods for inhibiting cell death: This invention provides novel compounds and methods for promoting cell survival and/or plasticity, especially in neuronal cells, by targeting the microtubule End Binding (EB) proteins and other associated proteins (e.g., drebrin). Methods for identifying potential modulators of cell death/plasticity are also described.... Agent:

20150141346 - Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof: This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.... Agent:

20150141347 - Murine anti-ny-eso-1 t cell receptors: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting... Agent:

20150141348 - Sustained release sirna for ocular drug delivery: The present invention provides an ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the... Agent:

20150141349 - Method and composition for alleviating tumor symptoms: This invention relates to methods and compositions for treating carcinoid syndrome and other adverse symptoms associated with tumor-producing neuroendocrine tumors, said methods comprising administering a therapeutically effective amount of a vascular disrupting agent, or a pharmaceutically acceptable salt thereof, to a subject having a hormone producing neuroendocrine tumor. In preferred... Agent: Angiogene Pharmaceuticals Ltd.

20150141350 - Dendrimer based nanodevices for therapeutic and imaging purposes: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer,... Agent:

20150141351 - Solid pharmaceutical compositions: The present invention features solid pharmaceutical compositions comprising Compound 1 (or a pharmaceutically acceptable salt thereof), Compound 2 (or a pharmaceutically acceptable salt thereof), and ritonavir (a pharmaceutically acceptable salt thereof), which are co-formulated in amorphous solid dispersion comprising a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant.... Agent: Abbvie Deutschland Gmbh & Co. Kg

20150141352 - Bone loss preventing and bone regeneration or bone formation promoting pharmaceutical composition comprising muramyl dipeptide: The present invention relates to a bone regeneration or bone formation promoting pharmaceutical composition comprising muramyl dipeptide, an analogue thereof, a derivative thereof or a pharmaceutically acceptable salt thereof. In contrast to existing passive therapeutic agents which center on bone absorption suppression based on mechanisms for reducing osteoclast functionality, the... Agent: Snu R&db Foundation

20150141354 - Glycoside derivatives and uses thereof: e

20150141353 - Methods for treating hcv: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.... Agent:

20150141355 - Salacia compositions, methods of treatment by their administration, and methods of their preparation: A Salacia composition described herein significantly reduces appetite, activates Hormone Sensitive Lipase, and manages a healthy lipid profile through inhibition of HMG-CoA Reductase enzyme. Salacia compositions described herein include of at least 12% of polyphenols, 2% of mangiferin and 1% of 25,26-oxidofriedelane-1,3-dione by weight of the composition in the form... Agent:

20150141356 - Treatment of clostridium difficile infection in high risk patients: The present invention relates to methods of preventing and/or treating Clostridium difficile infection (CDI) in a subject at high risk for developing CDI including subjects receiving antibiotic therapy for a different infection comprising administering to the subject an effective amount of the compounds described herein.... Agent:

20150141357 - Shikimate pathway inhibitors and the use thereof: e

20150141358 - Reduced toxicity in alcoholic beverages: The present invention relates to reduced toxicity of functional alcoholic beverage composition comprising distilled alcohol, deionized water, 18β-Glycyrrhizin or 18α-Glycyrrhizin and a sugar alcohol or sugars, having pH in the range of 4.0-9.0. More particularly, alcoholic beverage composition comprises distilled alcohol, deionized water, 18β-Glycyrrhizin or 18α-Glycyrrhizin and a sugar alcohol/sugars... Agent: Chigurupati Technologies Private Limited

20150141359 - Controlled release formulations for the delivery of hif-1 inhibitors: Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some... Agent:

20150141360 - Biocidal compositions: A process for preparing a biocidal composition comprising the steps of: (i) dissolving at least one polyol in water to form a water/polyol co-solvent solution; (ii) adding at least one organic acid to the water/polyol co-solvent solution; (iii) adding at least one stabiliser to the water/polyol co-solvent solution; (iv) adding... Agent:

20150141361 - Use of epigenome-modifying compounds for the treatment of genetic muscular diseases linked to a protein-conformational disorder: A pharmaceutical composition including at least one epigenome-modifying compound, for a use thereof in the treatment of genetic muscular diseases linked to a conformational disorder of at least one protein, said disorder causing the cellular degradation of the protein.... Agent: Genethon

20150141493 - Antisense modulation of gccr expression: Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.... Agent: Isis Pharmaceuticals, Inc.

20150141486 - Composition comprising mirna for enhancing radiation sensitivity: Provided are a method of enhancing radiation sensitivity by using miR-499b-5p and a method of treating a radiation resistant cancer including administering miR-499b-5p.... Agent: Korea Institute Of Radiological & Medical Sciences

20150141495 - Differential expression of micrornas in nonfailing versus failing human hearts: The present invention discloses specific miRNAs as novel biomarkers and therapeutic targets in the treatment of heart failure. Methods of treating or preventing heart failure in a subject by administering mimics or inhibitors of these particular miRNAs are disclosed. A method of diagnosing or prognosing heart failure in a subject... Agent:

20150141489 - Methods of treating and diagnosing diseases using agents that regulate the alternative splicing pathway: A method of determining a treatment for an inflammatory disorder in a subject, is disclosed. The method comprises determining an amount of SRSF6 in a sample from the subject, wherein an amount of the SRSF6 is indicative of the treatment. Methods of diagnosing inflammatory disorders and treating same are also... Agent:

20150141484 - Methods, compositions and drug delivery systems for intraocular delivery of sirna molecules: Biocompatible intraocular drug delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.... Agent:

20150141487 - Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a... Agent: Quark Pharmaceuticals, Inc.

20150141485 - Prognosis and treatment of lung cancer using mirna-135b: The present invention provides a method for the prognosis of lung cancer patient based on the expression levels of miRNA-135b, LZTS1, LATS2 and nuclear TAZ. The invention also provides a method for treatment of lung cancer.... Agent: National Taiwan University

20150141490 - Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them: The present invention relates to pyrazolotriazolyl nucleoside analogues, oligonucleotide comprising them, and uses thereof. Further the invention relates to a method for reducing gene expression in a cell comprising transfecting the cell with such an oligonucleotide. It has been found, in accordance with the present invention, that certain pyrazolotriazolyl-based nucleoside... Agent:

20150141492 - Rna interference mediating small rna molecules: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like... Agent:

20150141488 - Small molecule inhibitors of rna binding motif (rbm) proteins for the treatment of acute cellular injury: the remaining R1-R8 are each independently selected from hydrogen, halo, hydroxyl, nitro, nitroso, amino, substituted amino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoy, alkenyloxy, substituted alkenyloxy, alkynyloxy, substituted alkynyloxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloalkynyl, substituted cycloalkynyl, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy,... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20150141491 - Therapeutic targets for alzheimer's disease: The present invention relates to novel methods for the prevention, treatment and diagnosis of Alzheimer's disease. In addition, the invention relates to methods for assessing an individual's susceptibility or pre-disposition to Alzheimer's disease. The methods of the present invention involve the use of therapeutic targets and diagnostic and/or predictive markers... Agent:

20150141494 - Treatement of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf: Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.... Agent:

20150141499 - Engineered nucleic acids and methods of use thereof: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of viruses. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent viral infection, or to improve a subject's heath... Agent:

20150141498 - Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids: The present invention is directed to (the use of) a solution containing at least one nucleic acid (sequence) and free mannose for lyophilization, transfection and/or injection, particularly of RNA and mRNA. The inventive solution exhibits a positive effect on stabilization of the nucleic acid (sequence) during lyophilization and storage but... Agent: Curevac Gmbh

20150141496 - Mcp-1 binding nucleic acids and use thereof: The present invention is related to a nucleic acid molecule capable of binding to MCP-I, whereby the nucleic acid molecule is for use as a medicament for the treatment and/or prevention of a chronic disease or chronic disorder, preferably selected from the group consisting of chronic respiratory disease, chronic kidney... Agent: Noxxon Pharma Ag

20150141497 - Methods for modulating kallikrein (klkb1) expression: Disclosed herein are methods for decreasing kallikrein and treating, preventing, or ameliorating metabolic conditions in an individual in need thereof. Examples of disease conditions that can be treated, prevented, or ameliorated with the administration of antisense compounds targeted to kallikrein include obesity and diabetes. Methods for inhibiting kallikrein can also... Agent: Joslin Diabetes Center, Inc.

20150141362 - Inhibitors of human ezh2, and methods of use thereof: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2,... Agent:

20150141363 - Substituted nucleotide analogs: Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.... Agent:

20150141364 - Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.... Agent: University Of South Florida

20150141365 - Uracyl spirooxetane nucleosides: The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R9 has the meaning as defined herein, or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone... Agent: Janssen R&d Ireland

20150141366 - Effective treatment of esophogeal adenocarcinoma using triciribine and related compounds: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a... Agent:

20150141367 - Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk: A prebiotic formulation for oral administration to a human comprising 2′-fucosyllactose, 3′-sialyllactose and 6′-sialyllactose, and a method for modulating or stimulating the growth of Bifidobacteria in the gut. The formulation may be an infant formula.... Agent:

20150141370 - Efficient production of oligosaccharides using metabolically engineered microorganisms: The present invention relates to the enzymatic synthesis of oligosaccharides, particularly, sialylated oligosaccharides comprising the carbohydrate moeities of the gangliosides GM3, GD3, and GT3.... Agent: Centre National De La Recherche Scientifique (cnrs)

20150141369 - Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate: Oral pentosan polysulfate (PPS) compositions treat diseases such as diabetes, inflammation, atherosclerosis. The compositions are also effective in reducing matrix metalloproteinases (MMPs).... Agent:

20150141368 - Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods: The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium... Agent: Mcneil-ppc, Inc.

20150141371 - Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia: A composition for use in a human by oral administration to reduce or control cardiometabolic risk factors associated with metabolic syndrome or hypercholesterolemia, or reduce risk of developing metabolic syndrome or hypercholesterolemia. The composition includes a combination of Arabinogalactan and Dihydroquercetin (taxifolin), where the Arabinogalactan is present in the combination... Agent:

20150141372 - Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer: Compounds of formula (I), processes for their production and their use as Bub1 kinase inhibitors for the treatment of hyperproliferative diseases and/or disorders responsive to induction of cell death.... Agent:

20150141373 - Osteoclast inhibitors for knee conditions: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.... Agent:

20150141374 - Osteoclast inhibitors for knee conditions: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.... Agent:

20150141375 - Methods of treating viral associated diseases: The present invention provides methods of treating diseases associated with at least one virus. The methods include administering a compound described in the invention in a therapeutically effective amount. According to some aspects of the present invention, the methods may further comprise at least one immunosuppressant agent to treat diseases... Agent:

20150141376 - Pharmaceutical compositions of anti-viral compounds and process for preparation thereof: Pharmaceutical compositions of anti-viral compounds, process for preparation and method of using the same are provided. Particularly, the present invention relates to chemically stable pharmaceutical compositions of efavirenz, emtricitabine and tenofovir disoproxil fumarate with optionally one or more pharmaceutically acceptable excipients, process for preparation and method for the treatment or... Agent:

20150141377 - Synergistic composition: A synergistic composition comprising a THP salt and a biopenetrant, in which the biopenetrant comprises a polymer of an unsaturated carboxylic acid or a copolymer of an unsaturated carboxylic acid with a sulphonic acid, said polymer or copolymer being terminated by a mono- or diphosphonated unsaturated carboxylic acid group or... Agent:

20150141378 - Nitroxyl progenitor compounds and methods of use: Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions.... Agent:

20150141379 - Tigecycline compositions and methods of preparation: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.... Agent:

20150141380 - Inhibitors of erk for developmental disorders of neuronal connectivity: A method of treating a subject at risk of or suspected of having Fragile X syndrome or autism spectrum disorder associated with abnormalities of ERK includes administering to the subject a therapeutically effective amount of at least one ERK inhibiting compound that prevents abnormalities in neuronal connectivity, a prodrug thereof... Agent: Case Western Reserve University

20150141381 - Tetracycline compounds having target therapeutic activities: Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.... Agent: Paratek Pharmaceuticals, Inc.

20150141383 - Darunavir polymorph and process for preparation thereof: There is disclosed crystalline darunavir hydrate substantially free of any non-aqueous solvent.... Agent:

20150141382 - Novel solvates of darunavir: The present invention relates to novel solvates of Darunavir of Formula I.... Agent:

20150141384 - Compositions and methods for the treatment of neurological degenerative disorders: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological degenerative disorders, may be formulated for oral,... Agent:

20150141385 - Methods useful for vitamin d deficiency and related disorders: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin... Agent:

20150141386 - Use of vitamin k to decrease allograft failure and patient mortality after organ transplantation: Poor vitamin K status is provided as an independent risk factor for allograft failure and mortality in patients who received organ transplantation and who are under immunosuppressive medication. Various forms and recommended dosages of vitamin K, optionally combined with vitamin D and/or other immunosuppressive medication, are provided to optimize the... Agent:

20150141387 - Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-benzamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a β2 adrenoceptor agonist; a CCR1 antagonist; a chemokine antagonist (not CCR1); a... Agent:

20150141388 - Delayed-release glucocorticoid treatment of rheumatoid disease: The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.... Agent:

20150141389 - Topical formulation compositions containing silicone based excipients to deliver actives to a substrate: The present disclosure relates to a semi-solid topical drug delivery formulation including a silicone-based excipient, at least one volatile solvent, at least one active configured to be topically delivered through a patient's skin for an intended therapeutic application, and at least one enhancer. The formulation may additionally optionally include at... Agent:

20150141390 - Plant steroids and uses thereof: The invention relates to a drug conjugate including a drug and a plant steroid. The drug conjugate may target the drug for intestinal cell delivery, and thus may be used to treat diseases, including intestinal diseases, or to affect intestinal metabolism. The invention therefore also relates to treating intestinal diseases... Agent: Davidson Lopez, LLC

20150141391 - Systems and methods for determining a treatment course of action: The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.... Agent:

20150141392 - Substituted macrocyclic compounds having proteasome inhibitory activity: The disclosure provides for novel compounds which have proteasome inhibitory activity, pharmaceutical compositions made thereof, and methods of use thereof to treat various disorders, including cancer and nonmalignant tumors.... Agent:

20150141393 - Enhanced preservative: A composition having biocidal properties is disclosed. The composition includes a first biocide, optionally a second biocide, and a biocide enhancing agent. The first biocide may comprise an isothiazolin. The second biocide may comprise a pyrithione. The biocide enhancing agent may comprise an amine, an amine salt, an amine oxide,... Agent:

20150141394 - Nitrogen containing compounds and their use: Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.... Agent: Wockhardt Ltd.

20150141399 - Mek inhibitors and methods of their use: m

20150141398 - Nampt inhibitors: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.... Agent:

20150141396 - Pyrimidine pyrazolyl derivatives: The present invention provides compounds of Formula (I) for the treatment of cancer, rheumatoid arthritis and other diseases.... Agent: Ares Trading S.a.

20150141397 - Substituted anilines as ccr(4) antagonists: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.... Agent:

20150141395 - Benzofuran derivatives for the treatment of hepatitis c: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent:

20150141403 - 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders: wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2... Agent:

20150141401 - Novel beta-lactamase inhibitor and process for preparing the same: wherein A represents Ra(Rb)N— or RcO—; B represents NH or NC1-6 alkyl; C represents benzyl, H or SO3M, wherein M represents H, an inorganic or an organic cation; Ra and Rb represent H, C1-6 alkyl or acyl; Rc represents C1-6 alkyl or a heterocyclyl; A is unsubstituted or substituted with... Agent: Meiji Seika Pharma Co., Ltd.

20150141402 - Purine derivatives: or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the... Agent: Pfizer Inc.

20150141400 - Quinazolinedione derivative: The present invention relates to quinazolinedione derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.... Agent:

20150141404 - Non-ionic vesicle formulations of calcium channel blockers: Disclosed are non-ionic surfactant vesicle formulations of calcium channel blockers, such as diltiazem, and methods of using the formulations for treating anal disorders.... Agent:

20150141405 - Treatment of respiratory depression: Tricyclic dibenzothiazepine compounds for use in the treatment of respiratory depression.... Agent:

20150141406 - Heterocyclic compound: i

20150141407 - N-aryl unsaturated fused ring tertiary amine compounds, preparation method and anti-tumor applications thereof: The present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, its preparation method, a pharmaceutical composition comprising the compound, and its use in manufacture of a medicament for treatment of a disease or disorder, wherein R1, R2, R5, R6, X, Y, Q, W, n1... Agent: Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.l.a. China

20150141408 - Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors: The present invention relates to tricyclic pyrrolo derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such... Agent: Nerviano Medical Sciences S.r.l.

20150141409 - Novel revamipide prodrugs, preparation method and use thereof: Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided. The rebamipide prodrug is increased 25-fold in absorption rate compared to rebamipide itself, and can be applied to the prophylaxis... Agent:

20150141410 - Gpr17 receptor modulators: Chemical compounds are provided which act on GPR17 receptors and are useful in the treatment or amelioration of chronic and/or acute neurodegenerative diseases, such as multiple sclerosis, inflammatory diseases, pathologies involving the immune system, cardiovascular diseases, and renal diseases.... Agent: Fondazione Italiana Sclerosi Multipla - Fish Onlus

20150141411 - Substituted 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives useful for the treatment of (inter alia) alzheimer's disease: The present invention is concerned with novel substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione derivatives of Formula (I) wherein R1, R2, R3, R4, R5, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing... Agent:

20150141412 - Production of sterile active pharmaceutical ingredients: The invention refers to a process for preparing sterile active pharmaceutical ingredients (APIs) useful in the preparation of sterile product for ophthalmic use. The process comprises the gamma-ray sterilization treatment of the APIs powder in a protective atmosphere.... Agent: Icrom Spa

20150141413 - 5-amino[1,4]thiazines as bace 1 inhibitors: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.... Agent:

20150141414 - Formulation of stable recombinant alpha-fetoprotein conjugated with anti-tumor substance in target-delivery system for treatment of cancer and autoimmune disease: Disclosed is a stable formulation based on rAFP conjugated with drug delivery system of various classes of pharmacological agents such as dactinomycin, cardionolide, and bufadinolide, among others. In another embodiment, the invention discloses a method of producing rAFP in a strain of methylotrophic Pichia pastoris yeast, allowing the yeast to... Agent: Legrand International LLC

20150141415 - Methionine aminopeptidase inhibitors for treating infectious diseases: The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivatives thereof or a pharmaceutical... Agent:

20150141416 - Hydroxybupropion analogues for treating drug dependence: The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic... Agent: Virginia Commonwealth University

20150141417 - Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits... Agent:

20150141418 - Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control: The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production.... Agent: Ptc Therapeutics, Inc.

20150141419 - Diaryl[a, g]quinolizidine compound, preparation method therefor, pharmaceutical composition, and uses thereof: The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing... Agent:

20150141420 - Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma: The present invention relates to the use of 2,3-dihydroimidazo[1,2-c]quinazoline compounds, and of pharmaceutical compositions containing such compounds, for the treatment or prophylaxis of multiple myeloma, as a sole agent or in combination with other one or more other active ingredients.... Agent:

20150141421 - 6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors: Methods of inhibiting a receptor tyrosine kinase in a subject in need thereof. Methods of inhibiting the growth of a tumor cell in a subject in need thereof. Methods of treating pancreatic cancer in a subject in need of treatment for pancreatic cancer. Methods of treating HER2 positive breast cancer... Agent:

20150141422 - Heterocyclic compounds for the inhibition of pask: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.... Agent:

20150141424 - Ire-1alpha inhibitors: Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.... Agent:

20150141423 - Pesticidally active pyridyl- and pyrimidyl- substituted thiazole derivatives: Disclosed are pesticidally active pyridyl- and pyrimidyl-substituted thiazole derivatives, processes for their preparation, compositions comprising those compounds, and their use for controlling insects.... Agent: Syngenta Participations Ag

20150141425 - C5ar antagonists: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.... Agent:

20150141427 - Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1: The present invention relates to compounds of formula I: in which Y, Y1, Y4, Y5, Y6, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds... Agent: Novartis Ag

20150141426 - Dosage regimen for a pi-3 kinase inhibitor: The present invention relates to a dosage regimen for a phosphatidylinositol 3-kinase (PI3K) inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a dosage regimen for the treatment of patients suffering from a proliferative disease, such as, for example, cancer, with... Agent:

20150141428 - Trka kinase inhibitors, compositions and methods thereof: The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder... Agent: Merck Sharp & Dohme Corp.

20150141429 - Parp inhibitor compounds, compositions and methods of use: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or... Agent: Eisai Inc.

20150141430 - Method for modulating canonical wnt pathway using folate and inositol: The canonical Wnt signaling pathway is implicated in wound healing. Administration of a composition having myo-inositol and folic acid upregulates fibronectin and provides the greatest protection in an additive/synergistic manner against adverse Wnt/β-catenin-mediated effects on cell processes relating to cell differentiation, proliferation, and migration that relate to wound healing.... Agent: University Of South Florida

20150141431 - Pyrazinoisoquinoline compounds: where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that:... Agent: Concert Pharmaceuticals, Inc.

20150141432 - Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists: The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect... Agent:

20150141433 - N-arylmethyl sulfonamide negative modulators of nr2a: Compounds that selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.... Agent:

20150141434 - Pyridine and piperidine derivatives and use thereof: or pharmaceutically acceptable salts, solvates, hydrates, or diastereomers thereof, wherein R1, R4, X, G, n, p, W1, W2, W3, W4, and the E ring are defined in the disclosure. In certain embodiments, the invention provides compounds of Formulae II-XIII as set forth supra. The invention also provides the use of... Agent:

20150141435 - 2-pyridone antimicrobial compositions:

20150141436 - Indoles:

20150141437 - Amidophenoxypropanolamines: The use of compounds of formula wherein R2, R3, R4, R5, R6 and R7 have several meanings, for the treatment of disorders mediated by protozoan organisms, novel compounds of the above formula and intermediates for the preparation of such compounds, pharmaceutical compositions comprising such novel compounds, a method of treating... Agent:

20150141438 - Methods for delaying or preventing the onset of type 1 diabetes: Described herein are methods for preventing or delaying the onset of Type 1 Diabetes, or inhibiting the maturation of anti-insulin B cells, in an individual in need thereof. The methods include administering to an individual in need thereof ibrutinib, alone or in combination with other Type 1 Diabetes treatments.... Agent:

20150141439 - Pharmaceutical composition for the prevention or treatment of brain tumor or temodal resistant glioblastoma multiform comprising azathioprine as an active ingredient: The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer or Temodal resistant glioblastoma multiform comprising azathioprine as an active ingredient. The azathioprine of the present invention is not only effective in inhibiting the growth of glioblastoma multiform, a kind of brain tumor, but also... Agent:

20150141440 - Pharmaceutical composition for headache relief: A pharmaceutical composition for headache relief combines a vasoconstricting agent, a pain relief agent, and a disposition altering agent for a three-pronged approach to headache or migraine relief.... Agent:

20150141441 - Augmented cognitive training: The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining... Agent:

20150141442 - Chemical entities and therapeutic uses thereof: Certain chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with PB kinase activity are described.... Agent:

20150141443 - Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof: Provided herein is an optically active pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a... Agent:

20150141444 - N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators: The present invention is directed to N-methyl tetrahydroquinoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to... Agent: Merck Sharp & Dohme Corp.

20150141445 - Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof: The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other... Agent:

20150141446 - Pesticidal pyrimidine compounds: Pyrimidine compounds and their use in controlling pests such as insects and other invertebrates are provided. Further embodiments, forms, objects, features, advantages, aspects and benefits shall become apparent from the description.... Agent:

20150141447 - Solid preparation: The present invention provides a solid preparation excellent in disintegration property and preservation stability. The present invention relates to a solid preparation containing (1) 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof, (2) a saccharide, and (3) sodium stearyl fumarate. In addition, the present invention relates to a solid preparation containing... Agent: Takeda Pharmaceutical Company Limited

20150141449 - Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof: The present invention relates in general to the field of organic chemistry and in particular to the preparation of N-(4-(4-fluorophenyl)-6-isopropyl-5-methylpyrimidin-2-yl)-N-methylmethanesulfonamide (I), N-(4-(4-fluorophenyl)-5-(bromomethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (II) and N-(4-(4-fluorophenyl)-5-(hydroxymethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (III), key intermediates in preparation of Rosuvastatin.... Agent:

20150141448 - Topical ophthalmological pharmaceutical composition containing pazopanib: The present invention relates to topical ophthalmological pharmaceutical compositions containing pazopanib, a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and its process of preparation and its use for treating ophthalmological disorders.... Agent: Bayer Healthcare LLC

20150141450 - Methods of treating traveler's diarrhea and hepatic encephalopathy: Treatment of traveler's diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin.... Agent:

20150141451 - Compositions and methods for the treatment of chronic pain: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating chronic pain in a... Agent:

20150141452 - Compositions for affecting weight loss: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are... Agent:

20150141453 - Trigger-responsive chain-shattering polymers: Disclosed are polymers containing a backbone comprising alternating N-protected hydroxymethylaniline units (“spacer”) and linker units.... Agent:

20150141454 - Liquid pharmaceutical formulations of palonosetron: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.... Agent: Roche Palo Alto LLC

20150141455 - Complement pathway modulators and uses thereof: The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.... Agent: Novartis Ag

20150141456 - Cyclic amino compounds for use in the treatment of cardiac disorders: The present invention relates to tertiary amines of formula (I) for use in therapy, particularly for use in treating cardiovascular disorders. The compounds have been found to regulate phospholamban phosphorylation by interfering with the A-kinase anchor protein 18delta (AKAP18δ) binding to the PKA substrate phospholamban. The compounds share a tri(alkylaryl/alkylheteroaryl)... Agent:

20150141457 - Elvitegravir solid dispersion: The present invention provides a novel amorphous solid dispersion of elvitegravir in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. In a preferred embodiment the process for the preparation of amorphous solid dispersion of elvitegravir in combination with a pharmaceutically acceptable carrier comprises:... Agent:

20150141459 - Pharmaceutical compositions and administrations thereof: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions... Agent:

20150141458 - Treatment of glaucoma using laquinimod: The subject invention provides a method of treating a subject afflicted with glaucoma, suffering from retinal ganglion cell (RGC) loss or damage, or elevated intraocular pressure (IOP), or of reducing RGC loss or damage, or reducing IOP in a subject, comprising administering to the subject an amount of laquinimod effective... Agent: Teva Pharmaceutical Industries, Ltd.

20150141460 - Anti-inflammatory compositions: The invention relates to 3-(2′,2′-dimethylpropanoylamino)-tetrahydropyridin-2-one, and its pharmaceutical compositions and their use as a medicament intended to prevent or treat inflammatory disorders.... Agent:

20150141461 - Narcotic emulsion formulations for treatment of cancer pain: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent,... Agent:

20150141462 - Pharmaceutical compositions and methods for treating drug addiction and preventing a drug relapse: The present invention relates to pharmaceutical compositions comprising (a) a pharmaceutically effective amount of an mGluR5 positive allosteric modulator, derivative, prodrug or a pharmaceutically acceptable salt thereof; (b) a pharmaceutically effective amount of an agent selected from an NMDA partial agonist or a GlyT1 inhibitor, derivative, prodrug or a pharmaceutically... Agent:

20150141463 - Substituted pyrazolone compounds and methods of use: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the... Agent: Sunshine Lake Pharma Co., Ltd.

20150141464 - N-biphenylmethylbenzimidazole modulators of pparg: The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit cdk5 -mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or... Agent:

20150141465 - Compounds and uses thereof for the modulation of hemoglobin: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.... Agent:

20150141466 - Composition containing amino acid surfactants, betaines and n-methyl-n-acylglucamines and having improved foam quality and higher viscosity: The invention relates to a composition which contains at least one N-acyl-amino acid surfactant, a betaine surfactant, an N-methyl-N-acylglucamine, said N-methyl-N-acylglucamine having a C16-C20-acyl group, and further contains a solvent and optionally one or more additives. The invention also relates to a method for producing the composition. The invention further... Agent:

20150141467 - Solid forms of acetic acid, compositions, and uses thereof: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.... Agent:

20150141468 - Compositions and methods for the treatment of metabolic disorders: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing metabolic disorders may be formulated for oral, buccal,... Agent: Mahesh Kandula

20150141469 - Kit for producing foams containing bispyridinium alkane: A kit for the production of an antimicrobial foam includes: a) a liquid composition which includes a1)one or more bispyridinium alkane and a2)one or more surfactants selected from non-ionic surfactants, amphoteric surfactants and cation-active surfactants, wherein the composition is formulated so that a foam can be produced therefrom, and b)... Agent: L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georg

20150141472 - Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in... Agent:

20150141470 - Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a MAPK pathway inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and a GEF or HDAC inhibitor is provided. A method of treating cancer in a subject... Agent: Dana-farber Cancer Institute, Inc.

20150141471 - Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation: The present invention relates to compounds of the formula (I), wherein the residues R1 to R6, V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders... Agent:

20150141473 - Pharmaceutical dosage forms of tizanidine and administration routes thereof: A pharmaceutical composition in liquid dosage form which contains a tizanidine hydrocloride aqueous solution suitable for parenteral, intranasal and oral administration.... Agent: Mdm Spa

20150141474 - Cyclic ether dgat1 inhibitorscyclic ether dgat1 inhibitors: The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.... Agent: Novartis Ag

20150141475 - Therapeutic agent for food competence disorder in stomach: e

20150141476 - Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.... Agent:

20150141477 - Pyrazole derivatives and their use as lpar5 antagonists: The present invention relates to compounds of the formula (I), wherein the residues R1 to R5, V, G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders... Agent:

20150141478 - Series of drugs using photofrin to catalyze decomposition of hydrogen peroxide: The present invention relates to a series of new drugs which refer to chemical series capable of catalyzing the decomposition of H2O2 to generate singlet oxygen (1O2). The drugs relate to therapeutic mechanisms, different from traditional photodynamic therapy, in which the specific affinity of photofrin to focus, such as tumors,... Agent:

20150141479 - Compositions and methods for the treatment of moderate to severe pain: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating... Agent:

20150141480 - Carbohydrate-selective receptors: The present invention is directed to a new class of synthetic carbohydrate receptor compounds comprising Formula I as described herein: (I). Other aspects of the present invention relate to pharmaceutical compositions and pharmaceutical delivery vehicles comprising the compound of Formula (I) The present invention is also directed to methods of... Agent: New York University

20150141481 - Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration: Inhalation solutions for administration of beta 2-agonists or combinations of muscarinic antagonists and beta 2-agonists for the treatment of breathing disorders, such as COPD, are provided. The inhalation solutions are administered by nebulization, particularly with a high efficiency nebulizer.... Agent:

20150141482 - 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists: h

20150141483 - Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound: The invention provides crystalline hydrochloride salts of (S)-3-[(S)-2-methanesulfonyl-1-(4-trifluoromethylphenoxy)ethyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salts, processes and intermediates for preparing the crystalline salts, and methods of using the crystalline salts to treat diseases.... Agent: Theravance Biopharma R&d Ip, LLC

20150141500 - Compositions and methods for the treatment of neurological diseases: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases may be formulated for oral, buccal,... Agent:

20150141501 - Ultrapure tetrahydrocannabinol-11-oic acids: This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary... Agent:

20150141502 - Inhibition of leukemic stem cells by pp2a activating agents: A method of inhibiting the growth of leukemic hematopoietic stem cells in a subject with leukemia is described. The method includes administering a therapeutically effective amount of a composition including a compound of formula I: I wherein R1 is independently selected from hydrogen and methyl; R2 is selected from the... Agent: Ohio State Innvation Foundation

20150141503 - Solid, color-stable l-ascorbic acid compositions: The present invention relates to solid, color-stable L-ascorbic acid compositions, which are in the form of a powder or granule. These improved compositions have a high amount of vitamin C and they have excellent color stability.... Agent: DsmIPAssets B.v.

20150141504 - Complex zinc and alpha-chlorocarboxylic acid compounds for treating skin lesions: The invention relates to the field of medicine, and specifically to preparations for treating skin lesions, in particular viral, benign, precancerous and cancerous, non-metastasizing, dysplastic and inflammatory lesions of the visible mucous membranes, and also viral and fungal skin and nail lesions, and for correcting wrinkles and senile pigment blemishes,... Agent: Obschestvo S Ogranitchennoi Otvetstvennostju "oxygon"

20150141505 - Broncholytic drug on the basis of prostaglandin: The invention relates to the field of medicine, and specifically to pulmonology, and concerns a method for treating inflammatory and obstructive diseases of the airways, in particular bronchial asthma and obstructive bronchitis, with the aid of a drug on the basis of 1′,3′-dinitroglycerol ester 11(S),15(S)-dihydroxy-9-keto-5Z,13E-prostadienoic acid (nitroproston) having a marked... Agent:

20150141506 - Indane dimers for use in the treatment of autoimmune inflammatory disease: e

20150141507 - Melanoma chemoprevention: Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and/or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma,... Agent:

20150141509 - Method of treating ocular disorders with compounds found in harderian gland secretions: The present invention is directed to pharmaceutical compositions comprising compounds found in Harderian gland secretions, a method of treating dry eye in a human comprising ophthalmically administering an effective amount of a compound, e.g. a lipid compound, found in Harderian gland secretions, pharmaceutical compositions comprising said lipid compounds, as identified... Agent:

20150141508 - N-methyl-n-acylglucamine-containing composition: The invention relates to a clear composition which contains at least one anionic surfactant, a betaine surfactant, an N-methyl-N-acylglucamine, a triglyceride oil, a solvent and optionally an additive. The invention also relates to a method for producing the composition. The invention further relates to the use of the composition for... Agent: Clariant Finance (bvi) Limited

20150141510 - Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity c-reactive protein: The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum... Agent: Mochida Pharmaceutical Co., Ltd.

20150141511 - Dopaminergic mimetics: A method is described for providing acute symptomatic relief to a subject with Parkinson's Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic... Agent:

20150141512 - Polymer-based dialysate: Embodiments described herein provide a dialysate comprising a polyglycerol. The polyglycerol may be of a molecular weight between about 0.15 kDa and about 60 kDa. Also provided herein is the use of the dialysate as a diffusion agent and as an osmotic agent.... Agent: The University Of British Columbia

20150141513 - Compositions and methods for the treatment of neurological degenerative disorders and neurological diseases: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological degenerative disorders and neurological diseases may be... Agent:

20150141514 - Agent for preventing deterioration in vascular endothelial function or improving vascular endothelial function: An agent for enhancing NO production, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for... Agent:

20150141515 - Compositions and methods for delivery of nsaid and anesthetic: The invention relates generally to non-steroidal anti-inflammatory drugs (NSAIDs) and anesthetics, and more particularly, to NSAID and anesthetic compositions, methods of preparing/producing the compositions and methods of delivering, distributing and administering the compositions to patients.... Agent: Firstline Meds, Inc.

20150141516 - Formulations and methods for lyophilization and lyophilates provided thereby: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide... Agent:

20150141517 - Granulated composite, rapid release tablet and method for producing same: Provided is a rapid release tablet excellent in binding capability and disintegrability and also excellent in storage stability and the like. More specifically, provided are a granulated composite comprising low-substituted hydroxypropyl cellulose having a degree of hydroxypropoxy substitution of from 5 to 16% by weight and D-mannitol, wherein the D-mannitol... Agent:

20150141518 - Water-miscible stable solution composition for pharmaceutically active ingredients that are poorly soluble in water and susceptible to chemical degradation: A method to improve the stability of unstable drug substances in solution is described. Such solution compositions are water -miscible, can be refrigerated, sterilized and even co-administered with other pharmaceutical products without causing precipitation of the active ingredient. A particular example of such a stable, water-miscible solution composition for paracetamol... Agent:

20150141519 - Agomelatine sulfuric acid complex, and preparation method and application thereof: The present invention relates to an Agomelatine sulfuric acid complex in formula (I) and the preparation method thereof (HX=H2SO4, RSO3H (R=CH3, Ph, 4-CH3Ph)). The solubility of the Agomelatine sulfuric acid complex obtained by the method of the present invention is significantly improved compared with Agomelatine, has good stability and higher... Agent:

20150141520 - Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof: Stabilized pharmaceutical compositions comprising a S1P receptor modulator as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising fingolimod, or pharmaceutically acceptable salts, esters, hydrates and solvates thereof, process of preparation and method of using... Agent:

20150141521 - Small-molecule inhibitors of dengue virus proteases: The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.... Agent:

20150141522 - Active substance combination of licochalcone a and phenoxyethanol: Disclosed is a method for the treatment or prophylaxis of an inflammatory skin condition with cosmetic or pharmaceutical preparation which comprises licochalcone A and phenoxyethanol.... Agent: Beiersdorf Ag

20150141523 - Compounds for use in the treatment of autoimmune inflammatory disease: s

20150141524 - Method for the manufacture of bio-products with a modified sugar profile: The invention relates to a method for the production of a solid bio-product wherein at least 80% of the original indigestible oligosaccharide (raffmose, stachyose and verbascose) content has been degraded into digestible mono- and disaccharides, comprising the following steps: 1) providing a mixture of milled or flaked or otherwise disintegrated... Agent: Hamlet Protein A/s

20150141525 - Method for producing starch granules, and orally disinitegrating tablet: A method for producing starch granules suitable as an excipient for an orally disintegrating tablet. Fluidized bed granulation is performed by spraying a starch paste in small amounts while a β-starch is being fluidized using an air-fluidized bed. Subsequently, fluidized bed drying is performed at a temperature equal to or... Agent: Japan Corn Starch Co., Ltd.

20150141526 - Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection: The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an... Agent: Cosmo Technologies Ltd.

20150141527 - Sweet flavor modifier: The present invention includes compounds having structural formula (I), or salts or solvates thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of enhancing the sweet taste of compositions.... Agent:

20150141529 - Method and apparatus for treating centralized pain: A method for alleviating centralized pain in human subjects includes assessing the brain of a subject suffering from pain, diagnosing abnormal brain function associated with centralized pain, locating at least one area of abnormal brain function associated with the centralized pain, and alleviating the abnormal brain function by applying a... Agent:

20150141530 - Method and system for predicting recurrence and non-recurrence of melanoma using sentinel lymph node biomarkers: A method of characterizing melanoma in a subject involves determining the presence or level of one or more bio-markers in a sample obtained from a sentenal lymph node (SLN) of a subject.... Agent:

20150141528 - Neural specific s100b for biomarker assays and devices for detection of a neurological condition: An in vitro diagnostic (IVD) device is used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole... Agent: Banyan Biomarkers, Inc.

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20150611: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.

Advertise on FreshPatents.com - Rates & Info

###

FreshPatents.com Support - Terms & Conditions

Results in 0.39319 seconds

PATENT INFO